Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bayer AG is conducting an observational study titled ‘SMART-Finder – Identification of Patients With Elevated UACR Levels in a T2DM Cohort.’ The study aims to identify the prevalence of increased albumin levels in the urine among Type 2 Diabetes Mellitus (T2DM) patients using the myTherapy app in Germany. This research is significant as it addresses the gap in real-world data on chronic kidney disease (CKD) in T2DM patients.
Intervention/Treatment: The study involves T2DM patients using the myTherapy app, who are prescribed standard T2DM medications, including Finerenone (Kerendia, BAY94-8862). The focus is on observing the natural progression of albumin levels in urine over time.
Study Design: This is a cohort observational study with no specific allocation or intervention model. The primary purpose is to observe and record changes in UACR levels over a 12-month period using data from routine care.
Study Timeline: The study began on August 18, 2023, with data collection spanning from October 2022 to December 2024. The last update was submitted on July 31, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data analysis.
Market Implications: The study’s findings could impact Bayer’s stock performance by highlighting the effectiveness of Finerenone in managing CKD in T2DM patients. Positive results may boost investor confidence and position Bayer favorably against competitors in the diabetes treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.